Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Corbus Pharma (CRBP) Misses Q3 EPS by 4c, Revenues Miss
November 8, 2018 7:16 AM ESTCorbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.09 million versus the consensus estimate of $1.23 million.
The third quarter was marked by the completion of the Jenrin transaction, which we view as a... More
